Market Overview

Benzinga's Top Initiations

Related SPPI
H.C. Wainwright & Co. Sees Significant Upside Ahead For Spectrum Pharmaceuticals
Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI)
Related GALT
MLV & Co Has Positive Outlook On Galectin Therapeutics Inc
UPDATE: Aegis Capital Downgrades Galectin Therapeutics

Analysts at HC Wainwright initiated coverage on shares of Spectrum Pharmaceuticals (NASDAQ: SPPI) with a “buy” rating. The target price for Spectrum Pharmaceuticals is set to $15. Spectrum's shares closed at $8.49 on Friday.

Ascendiant Capital initiated coverage on shares of Galectin Therapeutics (NASDAQ: GALT) with a “buy” rating. The target price for Galectin Therapeutics is set to $13. Galectin Therapeutics' shares closed at $11.00 on Friday.

Analysts at Morgan Stanley initiated coverage on shares ITC Holdings (NYSE: ITC) with an “overweight” rating. The target price for ITC Holdings is set to $105. ITC's stock closed at $93.13 on Friday.

Atlantic Equities initiated coverage on shares of Facebook (NASDAQ: FB) with an “overweight” rating. The target price for Facebook is set to $63. Facebook's shares closed at $51.04 on Friday.

Latest Ratings for SPPI

DateFirmActionFromTo
Oct 2013HC WainwrightInitiates Coverage onBuy
Jul 2013JMP SecuritiesUpgradesMarket PerformMarket Outperform
Jun 2013Credit SuisseDowngradesNeutralUnderperform

View More Analyst Ratings for SPPI
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (FB + GALT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters